Hypersensitivity to Phosphodiesterase 3 Inhibition in Post-Traumatic Headache
Study Details
Study Description
Brief Summary
To investigate whether cilostazol (phosphodiesterase 3 inhibitor) induces headache with migraine-like features in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Cilostazol Oral administration of 200 mg cilostazol. |
Drug: Cilostazol
Study participants will be allocated to receive oral administration of 200 mg cilostazol.
|
Placebo Comparator: Placebo
|
Drug: Placebo
Study participants will be allocated to receive oral administration of placebo.
|
Outcome Measures
Primary Outcome Measures
- Incidence of Migraine-Like Headache [12 Hours]
Difference in incidence of headache with migraine-like features (0 to 12 hours) between cilostazol and placebo.
Secondary Outcome Measures
- Headache Intensity Scores [12 Hours]
Difference in area under the curve (AUC) for headache intensity scores (0 to 12 hours) between cilostazol and placebo.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age 18 to 65 years of age upon entry into screening
-
History of persistent headache attributed to mild traumatic injury to the head for ≥ 12 months and in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)
-
≥ 4 monthly headache days on average across the 3 months prior to screening
-
Provision of informed consent prior to initiation of any study-specific activities/procedures.
Exclusion Criteria:
-
1 mild traumatic injury to the head
-
History of any primary or secondary headache disorder prior to mild traumatic injury to the head (except for infrequent episodic tension-type headache)
-
History of moderate or severe injury to the head
-
History of whiplash injury
-
History of craniotomy
-
History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) than, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion
-
The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior
-
Female subjects of childbearing potential with a positive pregnancy test during any study visit
-
Cardiovascular disease of any kind, including cerebrovascular diseases
-
Hypertension (systolic blood pressure of ≥150 mmHg and/or diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day
-
Hypotension (systolic blood pressure of ≤90 mmHg and/or diastolic blood pressure of ≤50 mmHg)
-
Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion
-
Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start
-
Baseline headache intensity of >3 on an 11-point numeric rating scale (0 being no headache, 10 being the worst imaginable headache)
-
Baseline headache with migraine-like features or self-reported baseline headache that mimics the subjects' usual headache with migraine-like features
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Danish Headache Center
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- H-21067676